New arylbismuth(III) oxinates, PhBi(MeOx)2, (p-MeC6H4)Bi(Ox)2, (p-MeC6H4)Bi(MeOx)2, (p-CIC6H4)Bi(Ox)2, and (p-CIC6H4)Bi(MeOx)2 (Ox- = quinolin-8-olate and MeOx- = 2-methylquinolin-8-olate) have been prepared by reaction of the appropriate diarylbismuth chlorides with Na(Ox) or Na(MeOx) in the presence of 15-crown-5. An X-ray crystallographic study has shown PhBi(MeOx)2 to be a five coordinate monomer with distorted square pyramidal stereochemistry. Chelating MeOx ligands have a cisoid arrangement in the square plane and the phenyl group is apical. The lattice is stabilised by significant Π-Π interactions between centrosymmetric molecules. A range of these complexes has been shown to have high in vitro biological activity (comparable with or better than cisplatin) against L1210 leukaemia, the corresponding cisplatin resistant line, and a human ovarian cell line, SKOV-3. However, initial in vivo testing against a solid mouse plasmacytoma (PC6) and P388 leukaemia has not revealed significant activity.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Smith, K. A., Deacon, G. B., Jackson, W. R., Tiekink, E. R. T., Rainone, S., & Webster, L. K. (1998). Preparation and anti-tumour activity of some arylbismuth(iii) oxine complexes. Metal-Based Drugs, 5(5), 295–304. https://doi.org/10.1155/MBD.1998.295